Exact Sciences Corp. stock (US30063P1057): earnings beat and Abbott takeover reshape cancer diagnostics story

Exact Sciences Corp. has reported stronger-than-expected quarterly results while agreeing to a multibillion?dollar takeover by Abbott, putting fresh focus on its growth in cancer screening and what the deal could mean for shareholders and the broader US diagnostics market.

Exact Sciences Corp. has moved back into the spotlight after delivering a quarterly earnings beat and agreeing to be acquired by Abbott in a deal valued at around 21 billion US?dollars, reshaping the landscape for cancer diagnostics and raising questions about the future of its flagship Cologuard screening franchise, according to MarketBeat as of 05/2026 and Simply Wall St as of 05/2026.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Exact Sciences
• Sector/industry: Healthcare, molecular diagnostics
• Headquarters/country: Madison, Wisconsin, United States
• Core markets: United States cancer screening and diagnostics, with growing international presence
• Key revenue drivers: Cologuard colorectal cancer screening, Oncotype DX breast cancer testing, precision oncology portfolio
• Home exchange/listing venue: Nasdaq (ticker: EXAS)
• Trading currency: US?dollar (USD)

Exact Sciences Corp.: core business model

Exact Sciences Corp. focuses on molecular diagnostics for the early detection and management of cancer, with a strategy built around non?invasive tests that can be used at scale in routine clinical practice. The company aims to replace or complement traditional procedures such as colonoscopy by offering stool? and blood?based screening tools that are easier for patients to use, according to Exact Sciences company information as of 2026.

The best?known product is Cologuard, a stool?based DNA screening test for colorectal cancer intended for average?risk adults, which is prescribed by physicians and used at home by patients. This test is often reimbursed by major US health insurers and Medicare in appropriate age groups, making it a key gateway into the large and recurring colorectal screening market in the United States, according to Exact Sciences product information as of 2026.

Beyond screening, Exact Sciences has built a precision oncology portfolio with tests such as Oncotype DX, which provides genomic insights to guide treatment decisions in breast cancer and other tumor types. These assays are typically ordered by oncologists and can influence chemotherapy choices, positioning the company not only in early detection but also in ongoing cancer care, according to Exact Sciences test overview as of 2026.

The business model combines recurring test volumes, relationships with healthcare providers and payers, and continuous R&D investment to expand the menu of assays. Revenue largely depends on test ordering patterns, reimbursement levels, and the company’s ability to win guideline inclusions and long?term contracts with health systems, according to Exact Sciences newsroom as of 2026.

Main revenue and product drivers for Exact Sciences Corp.

Cologuard remains the central growth and revenue engine for Exact Sciences, supported by the scale of the US colorectal cancer screening market and guideline recommendations that encourage regular testing for adults starting at age 45 or 50. The company has invested in direct?to?consumer awareness campaigns and partnerships with primary care networks to increase adoption, according to Exact Sciences newsroom as of 2026.

The precision oncology segment adds a second pillar, with Oncotype DX and other genomic tests contributing higher?value assays per patient. These products can be less volume?intensive than screening tests but often carry premium pricing due to their impact on therapy selection, which can drive margins when reimbursement is secured, according to MarketBeat as of 05/2026.

In its most recently reported quarter, Exact Sciences posted earnings per share of 0.24 US?dollar, ahead of the 0.13 US?dollar consensus estimate, while revenue grew about 20 percent year over year, according to quarterly data compiled by MarketBeat as of 11/2025. That combination of top?line expansion and a positive earnings surprise has helped support confidence in the underlying business trajectory despite continued net losses over the trailing twelve months.

MarketBeat data show annual sales of roughly 3.25 billion US?dollars and a market capitalization of around 20 billion US?dollars for Exact Sciences, with net margins still negative at about minus 6.4 percent over the trailing twelve months, according to MarketBeat as of 05/2026. The figures highlight that the company is in a transition phase from growth?at?all?costs toward balancing expansion with profitability.

The balance sheet shows a debt?to?equity ratio near 0.97 and liquidity ratios above 2, which suggest Exact Sciences maintains financial flexibility but also carries leverage that requires ongoing cash generation and capital discipline, according to MarketBeat as of 05/2026. For investors, these metrics provide context on how the business has been financing its growth and how sensitive it might be to shifts in capital markets or interest rates.

Abbott’s planned takeover: what it means for Exact Sciences Corp.

Abbott recently closed, or is in the process of closing, an acquisition of Exact Sciences valued at roughly 21 billion US?dollars to strengthen its cancer diagnostics portfolio, according to an analysis of Abbott’s strategy by Simply Wall St as of 05/2026. The deal plugs Exact Sciences’ molecular tests into Abbott’s global distribution network and extensive installed base of diagnostic systems.

For Exact Sciences, integration into a diversified healthcare group could mean larger sales channels, greater resources for R&D, and more leverage in negotiations with payers and health systems. At the same time, it introduces integration risk, potential reprioritization of projects, and changes in management focus when a once?independent innovator becomes part of a much bigger organization, according to Simply Wall St as of 05/2026.

The takeover comes as Abbott faces its own legal and operational challenges in other business lines, particularly infant formula litigation and a securities class action, which could influence capital allocation and strategic priorities over time. While these issues are not directly tied to Exact Sciences’ product portfolio, they form part of the broader backdrop that could affect the combined company’s risk profile, according to Simply Wall St as of 05/2026.

From a stock?market perspective, deals of this size typically involve a mix of cash, shares, or both for existing shareholders, and may lead to the eventual delisting of the target company from Nasdaq once the transaction fully closes. Until closing, Exact Sciences continues to trade as a separate listing, and the share price often reflects the market’s assessment of deal certainty, regulatory risk, and the time value of money relative to the announced transaction terms, according to Nasdaq market data as of 05/2026.

Share price performance and valuation signals

According to Nasdaq data, Exact Sciences shares have traded in a 52?week range between approximately 38.81 and 104.98 US?dollars, with recent prices near the upper end of that band, implying strong gains over the past year, as reported by MarketBeat as of 05/2026. The move reflects both operational progress and expectations around the Abbott deal.

MarketBeat lists a consensus analyst rating of “Reduce” with an average price target of about 92.13 US?dollars, based on coverage from more than 20 analysts, according to MarketBeat as of 05/2026. The average target sits below the recent market price, suggesting that some analysts see limited upside from current levels on a standalone valuation basis, even if merger considerations influence trading.

With annual revenue around 3.25 billion US?dollars and a market capitalization near 20 billion US?dollars, the implied price?to?sales multiple is roughly 6.17, according to MarketBeat as of 05/2026. That valuation places Exact Sciences in the higher bracket of diagnostics companies, reflecting expectations of sustained growth in cancer testing volumes and potential margin expansion under Abbott’s ownership.

Despite the positive earnings surprise in the latest quarter, trailing twelve?month earnings remain negative, and the company does not pay a dividend, according to MarketBeat as of 05/2026. This profile indicates that the equity story has been driven more by revenue growth and strategic optionality than by current income returns.

Industry context: cancer screening and diagnostics

Exact Sciences operates in the broader cancer diagnostics and screening market, which has seen rising demand as medical guidelines emphasize early detection and health systems seek cost?effective ways to identify disease before it progresses. Non?invasive tests, including stool?based DNA assays and emerging blood?based minimal residual disease and multi?cancer screening technologies, are attracting significant investment, according to industry summaries from Janus Henderson as of 02/2026.

Within the United States, colorectal cancer screening is a particularly large and well?defined opportunity because insurers often cover testing and patients are increasingly aware of the benefits of early detection. Exact Sciences competes with traditional colonoscopy providers, fecal immunochemical tests, and other emerging tests, and must continually demonstrate clinical accuracy, convenience, and cost?effectiveness to maintain and grow its share, according to Exact Sciences newsroom as of 2026.

The precision oncology market segment is also evolving rapidly, with multiple companies offering genomic profiling, companion diagnostics, and minimal residual disease tests. Exact Sciences’ Oncotype DX brand is well?established in breast cancer, but the company faces competition from global diagnostics players and specialized genomics firms, which keeps pressure on innovation and commercial execution, according to Exact Sciences test overview as of 2026.

Regulatory frameworks, reimbursement decisions, and evolving clinical guidelines play decisive roles in this industry. Delays or negative outcomes in any of these areas can slow adoption, while positive decisions can open up large new patient populations. For Exact Sciences and Abbott, close alignment with regulators and medical societies is therefore a critical strategic priority, according to Exact Sciences newsroom as of 2026.

Why Exact Sciences Corp. matters for US investors

For US investors, Exact Sciences offers exposure to the intersection of biotechnology, diagnostics, and population?level screening programs. The company’s revenue base is heavily weighted toward the United States, where reimbursement structures and healthcare policies directly influence volumes and pricing, according to Exact Sciences company information as of 2026.

The Nasdaq listing under ticker EXAS places the stock within the universe of US growth and healthcare names followed by institutional funds and retail traders. Because Exact Sciences is in a space often associated with high innovation but also significant regulatory and execution risk, it can contribute to portfolio volatility and sector diversification, according to trading data compiled by Nasdaq as of 05/2026.

The planned Abbott acquisition adds another layer of relevance: it illustrates how large, diversified healthcare groups are willing to pay substantial sums for diagnostics platforms with established reimbursement and scale in the US market. For observers of the broader sector, this transaction provides a reference point for valuations and strategic priorities in cancer screening and molecular testing, according to Simply Wall St as of 05/2026.

Conclusion

Exact Sciences Corp. sits at a pivotal moment, combining robust revenue growth and an earnings beat with the transformative prospect of being folded into Abbott’s global diagnostics platform. The company has carved out a strong position in colorectal cancer screening and precision oncology, but still operates with negative net margins and no dividend, leaving the equity story centered on growth and strategic value rather than current income. For investors watching the US healthcare space, the stock offers a case study in how innovative diagnostics businesses can scale, attract large?cap suitors, and navigate the trade?offs between independence and integration into a diversified group, all under the scrutiny of regulators, payers, and a competitive landscape that continues to evolve.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.